The FDA has accepted for review the BLA for lerodalcibep to reduce LDL-C in patients with or high risk of ASCVD and primary hyperlipidemia.

Verve Therapeutics has started dosing patients in a phase 1b trial of its in vivo gene-editing drug for high cholesterol, designed to permanently switch off the PCSK9 gene with a one-shot treatment.

AstraZeneca has bought rights to an orally-active drug that inhibits PCSK9, offering a patient-friendly alternative to current cholesterol-lowering therapies that have to be delivered via a needle.

A Prescription Drug User Fee Act target date of December ... third generation proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor with an enhanced plasma half-life (between 12 and ...

Researchers developed an epigenetic editing approach to silence the PCSK9 gene, achieving long-term cholesterol reduction ...

At recent prices, you can buy shares of Merck (NYSE: MRK) that offer a yield above 3%, and shares of Pfizer (NYSE: PFE) offer ...

New dyslipidemia guidance from the American Association of Clinical Endocrinology focuses on newer medications and patient-important outcomes.

LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company today announced the U.S. Food and Drug Administration (FDA) has ac ...

Trials will be included in which the comparator was a placebo, no treatment or other conventional lipid-lowing agents when the experimental intervention was PCSK9 inhibitors alone or in combination ...

To understand the full scope of this medication -- its effectiveness, risks, and who stands to benefit the most -- ...

PCSK9, which mediates post-translational destruction of LDL receptors, is raised in HoFH and is further raised by statins. LDL-C, following apheresis, quickly rebounds due to increased synthesis ...

在肝脏中对PCSK9进行表观遗传编辑，旨在诱导DNA甲基化和沉默基因表达，在表达人类PCSK9基因的转基因小鼠和食蟹猴中实现了LDL胆固醇水平的长期降低。 靶向人类 PCSK9 的强效表观遗传编辑器：降低低密度脂蛋白胆固醇水平的新突破 近日，来自 Chroma Medicine 的 ...